Drug
Cyclosporine Ophthalmic Emulsion clinical trials
- studies test it
- 18
- open now
- 0
- in phase 3
- 2
- first study started
- 2004
How studies write it
Studies that test it under each name
Combined with it in one product
- Restasis
- 10
Studies by the year they started
18 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2013 | 2 |
| 2015 | 1 |
| 2018 | 1 |
| 2021 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 2
- Phase 2
- 7
- Phase 3
- 2
- Phase 4
- 4
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 12
Allergan (3) · Boston Sight (2) · OphRx Ltd. (1) · University of Alabama at Birmingham (1) · Federal University of São Paulo (1) · Bausch & Lomb Incorporated (1) · Seref istek (1) · University of North Carolina, Chapel Hill (1)
Often tested with
Tested in the same studies.
Cyclosporine (12) · Loteprednol Etabonate (2) · Arsenic (1) · Lubricant Eye Drops (1)
Studies
Open first, then newest update. How each study uses Cyclosporine Ophthalmic Emulsion is read from its arms, and is right about nine times in ten.
Testing it · 18
- Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE DeviceCompletedPhase 1/2Boston SightNCT04918823Written as Restasis
- A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy VolunteersCompletedEarly Phase 1OphRx Ltd.NCT05184517Written as Restasis
- Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens WearersCompletedNot applicableUniversity of Alabama at BirminghamNCT00335114Written as cyclosporine ophthalmic emulsion
- Novel Use of Restasis and PROSE DevicesWithdrawnPhase 3Boston SightNCT04735510Written as cyclosporine ophthalmic emulsion 0.05%
- Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye DiseaseCompletedPhase 4Federal University of São PauloNCT02004067Written as Restasis
- Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)CompletedPhase 2Bausch & Lomb IncorporatedNCT01817582Written as Restasis
- The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye SyndromeCompletedPhase 4Seref istekNCT03666884Written as COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
- Corneal Tear Film Imaging of the Cornea Before and After Restasis TherapyStatus unknownNot applicableMeir Medical CenterNCT03403023Written as Restasis
- Topical Cyclosporine Suspension for the Treatment of Brittle NailsCompletedPhase 2University of North Carolina, Chapel HillNCT01064830Written as topical cyclosporine ophthalmic suspension 0.05%
- Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure DisorderCompletedPhase 3Vanderbilt-Ingram Cancer CenterNCT00755040Written as cyclosporine ophthalmic emulsion
- Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?CompletedNot applicableWills EyeNCT00405431Written as Restasis
- Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry EyeCompletedPhase 1AllerganNCT01319773Written as cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%
- Restasis for Treatment of Brittle NailsCompletedPhase 2Julian M. Mackay-WigganNCT00986427Written as Restasis (cyclosporine ophthalmic emulsion) 0.05%
- Topical Cyclosporine vs. Placebo for Epiphora Associated With DocetaxelWithdrawnPhase 2M.D. Anderson Cancer CenterNCT00824811Written as Cyclosporine Eye Drops (Restasis)
- Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary PterygiumCompletedPhase 2AllerganNCT01109056Written as cyclosporine ophthalmic emulsion 0.05%
- Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK PatientsCompletedPhase 2AllerganNCT00611403Written as Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)
- Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With RestasisCompletedPhase 4Ophthalmic Consultants of Long IslandNCT00407043Written as Restasis
- Topical Cyclosporine and Disease ProgressionCompletedPhase 4Innovative MedicalNCT00567983Written as Restasis
Given in every arm · 1 — Cyclosporine Ophthalmic Emulsion is usual care beside what is tested
As the comparator · 9 — what is tested is compared with Cyclosporine Ophthalmic Emulsion
- Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)CompletedNot applicableSight Sciences, Inc.NCT04795752Written as Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
- HU007 in Patients with Dry Eye SyndromeCompletedPhase 3Huons Co., Ltd.NCT05743764Written as Restasis
- Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to RestasisCompletedPhase 2SCAI TherapeuticsNCT05733624Written as Restasis 0.05% eyedrop
- Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye DiseaseCompletedPhase 2Aurinia Pharmaceuticals Inc.NCT03597139Written as Restasis®
- Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye SyndromeCompletedPhase 3Huons Co., Ltd.NCT03461575Written as Restasis
- Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye SyndromeCompletedPhase 2Huons Co., Ltd.NCT02917512Written as Restasis
- Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%CompletedNot applicableUniversity of MichiganNCT01695668Written as Restasis
- Efficacy and Safety of HE10 for Dry Eye SyndromeCompletedPhase 3Huons Co., Ltd.NCT02492412Written as Restasis
- Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye SyndromesCompletedPhase 3Taejoon Pharmaceutical Co., Ltd.NCT02461719Written as Restasis